...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith share issue

The presentations have said the company will issue 10MM shares shortly not raise $10MM.  Hopefully the share issue is done in that $3US neighbourhood. I agree that price would perhaps be good for validation of the science of both companies. 

Share
New Message
Please login to post a reply